Your Brain Can Change. Neurofeedback Therapy Helps It Happen.

Neurofeedback, also called EEG biofeedback or neurotherapy, is a non-invasive form of operant conditioning of brain activity. Sensors placed on the scalp measure electrical activity (electroencephalography, EEG) in real time, and a computer translates those brainwave patterns into visual or auditory feedback — typically a video game, movie, or sound that rewards the brain when it produces the targeted pattern and pauses when it does not. Over repeated sessions, the brain learns to self-regulate toward more efficient patterns of activation, a process supported by neuroplasticity. Neurofeedback has been used clinically since the 1960s and is now studied for ADHD, anxiety, depression, PTSD, epilepsy, insomnia, migraines, and peak performance.

Neurofeedback works through three mechanisms: (a) operant conditioning — the brain is rewarded (with on-screen progress, sound, or visual feedback) when it produces a desired EEG pattern, increasing the probability of that pattern recurring; (b) classical conditioning — repeated pairing of brain states with feedback signals strengthens self-regulation; and (c) skill learning and neuroplasticity — over 20–40 sessions the brain forms new functional connections and stabilizes more adaptive arousal states, with measurable changes seen on QEEG and fMRI. Importantly, the learning is implicit; clients do not need to consciously “do” anything during a session — the brain learns from the feedback automatically.

Yes — for several conditions neurofeedback has substantial peer-reviewed evidence, while for others it is still emerging. The American Academy of Pediatrics and Division 53 of the American Psychological Association have rated neurofeedback as a “Level 1 — Best Support” intervention for ADHD in children. Multiple meta-analyses show medium-to-large effect sizes on inattention and impulsivity. Evidence is also rated efficacious or probably efficacious for epilepsy, anxiety, and substance use disorders, and probably efficacious for insomnia, depression, and migraines according to the standardized rating system used in Applied Psychophysiology and Biofeedback. Critics point out that some sham-controlled trials show smaller effects, suggesting non-specific factors also contribute — but recent standard-protocol trials and learning-based analyses confirm condition-specific brain changes.

Neurofeedback is evidence-based for several conditions, though the placebo question is legitimately debated. Sham-controlled randomized trials have produced mixed results: some show neurofeedback outperforms sham, others show comparable improvements. However, more rigorous analyses that separate “learners” (those who successfully modulate their EEG) from “non-learners” find significantly greater symptom improvement in learners — evidence that the EEG learning itself drives the clinical effect, not just expectation. Standard protocols (theta/beta for ADHD, SMR for epilepsy and insomnia, alpha-theta for trauma and addiction) have replicated efficacy across independent labs.

QEEG, or quantitative EEG, is a digital analysis of the brain’s electrical activity recorded from 19 or more scalp sensors. The recording is compared against a normative database of healthy brains matched for age and sex, producing colour-coded “brain maps” that show where activity is statistically different from typical. QEEG is used to identify dysregulated regions and networks, guide individualized neurofeedback protocols, and track progress over treatment. QEEG patterns are reliably associated with conditions such as ADHD, depression, anxiety, traumatic brain injury, and dementia, though QEEG alone is not a diagnostic test.

Neurofeedback is a specialized type of biofeedback. Biofeedback is the broader category of training people to self-regulate physiological signals — heart rate, breathing, skin conductance, muscle tension, or brainwaves. Neurofeedback specifically targets brainwave activity measured by EEG. The two are often combined; for example, heart-rate variability (HRV) biofeedback is frequently used alongside neurofeedback for anxiety and PTSD.

This is the most-researched application of neurofeedback. Multiple meta-analyses and randomized controlled trials show medium-to-large effect sizes on attention and impulsivity, with effects that persist 6–12 months after treatment ends — a profile distinct from stimulant medication, which works only while taken. The standard theta/beta protocol downtrains slow (theta) waves and uptrains faster (beta or SMR) waves over the sensorimotor and frontal cortices. The American Academy of Pediatrics’ 2019 ADHD clinical practice guideline lists neurofeedback among non-pharmacological options, and the APA Division 53 has assigned it “Level 1 — Best Support” status for childhood ADHD.

Yes — peer-reviewed evidence supports neurofeedback for generalized anxiety, social anxiety, and performance anxiety. A 2020 meta-analysis of randomized trials reported significant reductions in anxiety symptoms with medium effect sizes. Common protocols include alpha uptraining (to reduce hyperarousal), SMR uptraining (to stabilize the nervous system), and infra-low frequency (ILF) training. fMRI-guided real-time neurofeedback targeting the amygdala has also shown promise, with patients learning to downregulate amygdala reactivity within 1–3 sessions.

Neurofeedback is rated “probably efficacious” for depression. The two main approaches are (a) frontal alpha asymmetry training, which addresses the relative hypoactivation of the left frontal cortex commonly seen in depression, and (b) real-time fMRI neurofeedback of emotion-regulation networks, which has shown clinically significant antidepressant effects in randomized controlled trials. A 2019 systematic review concluded that neurofeedback produces moderate improvements in depressive symptoms, particularly when combined with psychotherapy.

Yes. A 2016 randomized controlled trial published in PLOS ONE by van der Kolk and colleagues found that 24 sessions of neurofeedback produced significant and lasting reductions in PTSD symptoms compared with a waitlist control, with 73% of the treatment group no longer meeting PTSD criteria after treatment. Subsequent trials and meta-analytic work have replicated meaningful symptom reductions, particularly with alpha-theta protocols and infra-low frequency (ILF) training. Real-time fMRI amygdala-downregulation neurofeedback has also reduced PTSD symptom severity in veterans.

Research on neurofeedback for autism is promising but still emerging. Several studies, including randomized trials, have reported improvements in attention, executive function, and social communication after 20–40 sessions, particularly using mu-rhythm and theta/beta protocols. A 2020 systematic review concluded that neurofeedback shows positive effects on core and comorbid symptoms but called for larger sham-controlled trials before recommending it as a stand-alone treatment. It is best viewed as a complementary intervention used alongside behavioural and educational supports.

Yes — neurofeedback combined with biofeedback is rated “probably efficacious” for migraines. A 2010 review in Applied Psychophysiology and Biofeedback reported a 54% average reduction in migraine frequency with neurofeedback, compared with 39% reduction with medication alone. Subsequent trials using SMR and infra-low frequency protocols have replicated reductions in headache frequency, intensity, and medication use.

Sensorimotor rhythm (SMR) neurofeedback — uptraining 12–15 Hz activity over the sensorimotor cortex — has been shown to improve sleep onset latency, total sleep time, and sleep spindle density in randomized controlled trials. A 2020 systematic review of 11 studies concluded that SMR neurofeedback produces meaningful improvements in primary insomnia, with effects lasting at follow-up.

Evidence for OCD is preliminary but encouraging. Open-label trials and small RCTs report symptom reductions of 30–50% on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) following 20–40 sessions, often using protocols that downtrain excess beta in frontal regions. Real-time fMRI neurofeedback targeting the orbitofrontal cortex has also shown OCD symptom reductions in early trials.

Multiple peer-reviewed studies show that neurofeedback — typically guided by individualized QEEG mapping — can reduce post-concussion symptoms (headaches, brain fog, fatigue, attention difficulties, irritability) and normalize EEG patterns in patients with mild TBI. A 2019 systematic review concluded that EEG-biofeedback is an effective rehabilitation tool for cognitive and emotional sequelae of TBI, though larger sham-controlled trials are still needed.

Neurofeedback for epilepsy has the longest research history of any application — Sterman’s original studies in the 1970s showed that SMR uptraining could reduce seizures in drug-resistant patients. A 2009 meta-analysis of 10 controlled studies concluded that 74% of patients had clinically meaningful seizure reductions, with an average reduction of more than 50%. Slow cortical potential (SCP) training is another evidence-based protocol. Neurofeedback is rated “efficacious” by the AAPB/ISNR rating system for drug-resistant epilepsy.

Neurofeedback has been studied as a non-pharmacological intervention for chronic pain, fibromyalgia, and complex regional pain syndrome. Randomized and controlled studies report meaningful reductions in pain intensity, fatigue, and depression, often with alpha-theta or infra-low frequency protocols. A 2017 systematic review concluded that neurofeedback produces moderate improvements in fibromyalgia symptoms, with sustained benefits at follow-up.

Early randomized trials suggest neurofeedback may improve memory and executive function in adults with mild cognitive impairment (MCI). A 2019 RCT found significant gains in delayed recall and processing speed after 30 sessions of theta/beta neurofeedback compared with controls. Trials in healthy older adults also show improvements in working memory and attention. Evidence in established Alzheimer’s dementia is more limited, and neurofeedback is best considered a complement, not a replacement, for medical care.

Yes — peer-reviewed studies show that EEG neurofeedback (typically uptraining alpha and downtraining delta over auditory cortex regions) can reduce tinnitus loudness and distress. A 2020 systematic review of 10 studies concluded that neurofeedback produces clinically meaningful tinnitus reductions, with effects lasting at follow-up.

Alpha-theta neurofeedback is the best-studied protocol for addiction. The “Peniston-Kulkosky” protocol, originally tested with veterans suffering from alcohol use disorder, produced abstinence rates of 80% at 3-year follow-up — far exceeding standard treatment. Subsequent RCTs and meta-analyses have replicated significant benefits for alcohol, opioid, and stimulant use disorders, particularly when combined with conventional addiction treatment. The AAPB/ISNR rates neurofeedback as “efficacious” for substance use disorders.

Yes — peak performance training is a well-established application. Randomized studies in elite athletes (golfers, archers, dancers, surgeons) and musicians have shown that neurofeedback improves attention, reaction time, performance under pressure, and “flow” states. SMR uptraining and alpha-theta protocols are most commonly used. A 2017 review of 17 controlled studies concluded that neurofeedback produces moderate-to-large improvements in athletic and cognitive performance in healthy individuals.

Pilot RCTs show that neurofeedback — particularly motor-imagery-based protocols using sensorimotor rhythm — can enhance motor recovery, attention, and depression after stroke when combined with standard rehabilitation. A 2018 systematic review concluded that EEG-neurofeedback is a promising adjunct to post-stroke rehabilitation, with the strongest evidence for upper-limb motor recovery.

A typical session is calm and effortless. Sensors are attached to the scalp with a conductive paste; nothing is implanted, and no electrical current is sent into the brain — the equipment only reads activity. You sit comfortably and watch a movie, listen to music, or play a video game that responds to your brainwaves: the screen brightens, the sound gets louder, or the game progresses when your brain produces the targeted pattern. Most people find sessions relaxing. There is nothing you have to consciously “do” — the brain learns from the feedback automatically.

A typical session lasts 30–50 minutes, with 20–40 minutes of actual feedback training plus a few minutes for sensor setup and a brief check-in. The first session is usually longer (60–90 minutes) because it includes intake, education, and sometimes a QEEG assessment.

Most clinical protocols call for 20–40 sessions, with 30 being typical. Some conditions (e.g., simple anxiety, peak performance) may improve in 15–20 sessions, while complex presentations (e.g., chronic PTSD, autism, severe ADHD) may require 40–60. Sessions are typically scheduled 2–3 times per week early in treatment and tapered as gains stabilize. Effects on EEG patterns and symptoms are usually noticeable by sessions 8–12.

Twice weekly is the standard recommendation, especially in the first 10–20 sessions, because closely spaced sessions promote consolidation of brain learning. Three times per week can accelerate progress for some clients. Going less than once per week tends to slow learning. Once gains are stabilized, “booster” sessions every few months may be used as needed.

For many conditions, yes — long-term follow-up studies show that improvements persist 6 months to 2 years after treatment ends, distinguishing neurofeedback from medications, which work only while taken. The mechanism is thought to be enduring neuroplastic change in self-regulatory circuits. Some clients return for occasional booster sessions, especially under stress.

Neurofeedback is non-invasive and generally very safe. No electrical current is delivered to the brain — sensors only read EEG activity. Side effects, when they occur, are usually mild and transient: temporary fatigue, mild headache, vivid dreams, or short-lived irritability, particularly when protocols need adjustment. Adverse events are rare and resolve quickly when the clinician modifies the protocol. This is why working with a board-certified clinician who individualizes protocols is important.

In rare cases, an inappropriately chosen protocol can produce temporary worsening of symptoms (e.g., increased anxiety, sleep disturbance), which is why protocol selection is individualized and adjusted based on response. With a qualified provider, these effects resolve quickly when the protocol is modified. There is no evidence that properly conducted neurofeedback causes lasting harm.

Yes — neurofeedback is widely studied and used in children, particularly for ADHD, learning disabilities, anxiety, autism, and tic disorders. The American Academy of Pediatrics’ 2019 ADHD guideline lists it among non-pharmacological options, and APA Division 53 has rated it “Level 1 — Best Support” for childhood ADHD. Studies enrolling children as young as 5 report no serious adverse events.

No. Neurofeedback equipment only reads brain activity from the scalp; no electricity, magnetism, or any other form of energy is delivered to the brain. This is fundamentally different from neurostimulation methods such as TMS or tDCS, which apply external energy. Decades of clinical use across hundreds of thousands of patients show no evidence of brain damage.

Both medication and neurofeedback are evidence-based for ADHD, but they work differently. Stimulants typically produce larger short-term effect sizes (around 0.7–1.0) but only work while taken. Neurofeedback shows medium effect sizes (0.4–0.6) but improvements persist after treatment ends, and long-term follow-up studies show effects similar to medication at 6–12 months. For some families, neurofeedback is a valuable alternative or complement to medication, especially when side effects are an issue.

Neurofeedback and cognitive-behavioural therapy (CBT) are complementary, not competing. CBT trains conscious thoughts and behaviours; neurofeedback trains the underlying nervous-system regulation that supports those changes. Trials combining the two for anxiety, PTSD, and depression often produce stronger and faster results than either alone.

Transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) actively deliver energy to the brain; neurofeedback does not — it only measures activity and provides feedback so the brain can learn to self-regulate. TMS has FDA clearance for treatment-resistant depression and OCD; tDCS is investigational. Each has its own evidence base. Neurofeedback’s advantages include no external energy, broader applicability (ADHD, anxiety, PTSD, peak performance), and durable effects after treatment ends.

Both promote self-regulation, but with different mechanisms. Meditation trains attention through deliberate practice; neurofeedback gives the brain real-time feedback about its own activity, accelerating the same kinds of changes (increased alpha, improved attention networks) seen with long-term meditators. Some clients find neurofeedback an easier entry point because the brain learns implicitly, without requiring sustained voluntary effort.

Neurofeedback typically targets five brainwave bands: delta (0.5–4 Hz, deep sleep), theta (4–8 Hz, drowsy/inattentive), alpha (8–12 Hz, calm focus), SMR/beta (12–20 Hz, active engagement), and high beta (20–30 Hz, hyperarousal). Standard protocols include theta/beta training (downtrain theta, uptrain beta) for ADHD, SMR uptraining for epilepsy and insomnia, alpha uptraining for anxiety, and alpha-theta training for trauma and addiction.

Alpha-theta training takes place with eyes closed, in a deeply relaxed state, where the brain produces both alpha (8–12 Hz) and theta (4–8 Hz) waves. Crossover between these two — alpha decreasing and theta increasing — has been associated with deeply relaxed, trance-like states in which trauma processing and emotional integration appear to occur. This is the protocol famously used in the Peniston-Kulkosky studies for alcohol use disorder and PTSD.

Infra-low frequency training (sometimes called “Othmer Method”) provides feedback on extremely slow EEG fluctuations below 0.5 Hz that reflect the brain’s basic regulatory rhythms. ILF protocols have shown clinical benefits for trauma, anxiety, migraines, and ADHD in case series and open trials, with growing controlled-trial support.

Z-score neurofeedback compares the client’s EEG in real time to a normative database and rewards moves toward typical values. LORETA (Low Resolution Electromagnetic Tomography) neurofeedback uses 19+ sensors and source-localization mathematics to train activity in deeper brain regions, including networks like the default-mode network involved in depression and rumination. Both are advanced protocols typically guided by QEEG.

In Canada, individual neurofeedback sessions typically range from CAD $120–$200 per session, with QEEG brain-mapping assessments running CAD $300–$600 depending on complexity [exact pricing varies by clinic]. A standard course of 30 sessions thus typically costs CAD $3,500–$6,000, comparable to a course of psychotherapy. At our Vancouver clinic, please contact us for current pricing and package options.

In British Columbia and across Canada, neurofeedback is often partially or fully covered when it is delivered by a Registered Psychologist as part of psychological services. Many extended health benefit plans (Pacific Blue Cross, Sun Life, Manulife, Canada Life, Green Shield, etc.) reimburse psychological services that include neurofeedback. Coverage details vary by plan — we recommend confirming with your provider before booking.

Consumer EEG headbands (Muse, FocusCalm, Mendi, Neurosity, etc.) provide simplified neurofeedback for relaxation, focus, or meditation training. Research suggests they can produce modest improvements in attention and stress in healthy users. However, they typically use 1–4 sensors versus 19+ in clinical systems, lack QEEG-guided individualized protocols, and are not designed to treat clinical conditions like ADHD, PTSD, or epilepsy. For clinical issues, professionally administered, individually tailored neurofeedback remains the standard of care.

EEG biofeedback devices have been cleared by the U.S. FDA for “relaxation training” since the 1990s, and several QEEG and neurofeedback systems have 510(k) clearance for clinical use. The American Academy of Pediatrics included neurofeedback among non-pharmacological ADHD options in its 2019 clinical practice guideline. The APA Division 53 (Society of Clinical Child and Adolescent Psychology) has rated it “Level 1 — Best Support” for ADHD. Health Canada also recognizes EEG biofeedback as a Class II medical device.

Look for: (1) a licensed mental-health professional (psychologist, physician, counsellor) as the primary provider; (2) board certification through BCIA (Biofeedback Certification International Alliance, which administers BCN — Board Certified in Neurofeedback); (3) use of QEEG or other assessment to individualize protocols rather than one-size-fits-all programs; (4) clear outcome tracking; and (5) realistic, science-based claims (no promises of cures). Membership in ISNR (International Society for Neuroregulation and Research) or AAPB (Association for Applied Psychophysiology and Biofeedback) is also a positive indicator.

Yes — neurofeedback is compatible with most psychiatric and neurological medications, and many clients are on stable medication regimens during treatment. Some studies have found that successful neurofeedback allows clients (with their physician’s supervision) to reduce or discontinue certain medications over time, particularly stimulants for ADHD. Medication changes should always be made in consultation with the prescribing physician.